Ignite Creation Date:
2025-12-24 @ 10:09 PM
Ignite Modification Date:
2025-12-30 @ 8:27 AM
Study NCT ID:
NCT04626635
Status:
RECRUITING
Last Update Posted:
2025-12-03
First Post:
2020-11-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C000627974', 'term': 'cemiplimab'}, {'id': 'D000068258', 'term': 'Bevacizumab'}, {'id': 'C000613803', 'term': 'trifluridine tipiracil drug combination'}], 'ancestors': [{'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 933}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2020-12-21', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2026-12-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-02', 'studyFirstSubmitDate': '2020-11-06', 'studyFirstSubmitQcDate': '2020-11-06', 'lastUpdatePostDateStruct': {'date': '2025-12-03', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2020-11-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-08-19', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The incidence of dose-limiting toxicities (DLTs) during the DLT period', 'timeFrame': 'Up to 6 weeks', 'description': 'Dose escalation'}, {'measure': 'Incidence and severity of treatment-emergent adverse events (TEAEs)', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'Dose escalation'}, {'measure': 'Incidence and severity of adverse events of special interest (AESIs)', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'Dose escalation'}, {'measure': 'Incidence and severity of serious adverse events (SAEs)', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'Dose escalation'}, {'measure': 'Incidence and severity of grade ≥3 laboratory abnormalities', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'Dose escalation'}, {'measure': 'Objective Response Rate (ORR)', 'timeFrame': 'Up to 5 years', 'description': 'Dose expansion'}], 'secondaryOutcomes': [{'measure': 'Concentrations of REGN7075 in serum', 'timeFrame': 'Up to 5 years', 'description': 'Dose escalation and dose expansion'}, {'measure': 'ORR', 'timeFrame': 'Up to 5 years', 'description': 'Dose escalation'}, {'measure': 'Progression free survival (PFS)', 'timeFrame': 'Up to 5 years', 'description': 'Dose escalation and dose expansion'}, {'measure': 'Duration of Response (DOR)', 'timeFrame': 'Up to 5 years', 'description': 'Dose escalation and dose expansion'}, {'measure': 'Disease control rate (DCR)', 'timeFrame': 'Up to 5 years', 'description': 'Dose escalation and dose expansion'}, {'measure': 'Complete response (CR) rate', 'timeFrame': 'Up to 5 years', 'description': 'Dose escalation and dose expansion'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'Up to 5 years', 'description': 'Dose escalation and dose expansion'}, {'measure': 'Incidence of anti-drug antibodies (ADA) to REGN7075', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'Dose escalation and dose expansion'}, {'measure': 'Titers of ADA to REGN7075', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'Dose escalation and dose expansion'}, {'measure': 'Incidence of ADA to cemiplimab', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'Dose escalation and dose expansion'}, {'measure': 'Titers of ADA to cemiplimab', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'Dose escalation and dose expansion'}, {'measure': 'The incidence and severity of TEAEs', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'Dose expansion'}, {'measure': 'The incidence and severity of AESIs', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'Dose expansion'}, {'measure': 'The incidence and severity of SAEs', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'Dose expansion'}, {'measure': 'The incidence and severity of grade ≥3 laboratory abnormalities', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'Dose expansion'}, {'measure': 'Patient reported Quality of Life (QoL) per EORTC QLQ-C30', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.'}, {'measure': 'Patient reported Quality of Life (QoL) per EORTC QLQ-CR29 in CRC patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.'}, {'measure': 'Patient reported Quality of Life (QoL) per EORTC QLQ-BR23 in breast cancer patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': "The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems."}, {'measure': 'Patient reported Quality of Life (QoL) per EORTC QLQ-LC13 in NSCLC patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain.\n\nThe scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much".'}, {'measure': 'Patient reported Quality of Life (QoL) per EORTC QLQ-HN35 in HNSCC patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses.\n\nThe questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4.'}, {'measure': 'Patient reported Quality of Life (QoL) per EQ-5D-5L', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.'}, {'measure': 'Patient reported symptoms per EORTC QLQ-C30', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.'}, {'measure': 'Patient reported symptoms per EORTC QLQ-CR29 in CRC patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). . Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.'}, {'measure': 'Patient reported symptoms per EORTC QLQ-BR23 in breast cancer patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': "The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems."}, {'measure': 'Patient reported symptoms per EORTC QLQ-LC13 in NSCLC patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain.\n\nThe scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much".'}, {'measure': 'Patient reported symptoms per EORTC QLQ-HN35 in HNSCC patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses.\n\nThe questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4.'}, {'measure': 'Patient reported symptoms per EQ-5D-5L', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.'}, {'measure': 'Patient reported functioning per EORTC QLQ-C30', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.'}, {'measure': 'Patient reported functioning per EORTC QLQ-CR29 in CRC patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.'}, {'measure': 'Patient reported functioning per EORTC QLQ-BR23 in breast cancer patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': "The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems."}, {'measure': 'Patient reported functioning per EORTC QLQ-LC13 in NSCLC patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain.\n\nThe scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much".'}, {'measure': 'Patient reported functioning per EORTC QLQ-HN35 in HNSCC patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses.\n\nThe questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4.'}, {'measure': 'Patient reported functioning per EQ-5D-5L', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.'}, {'measure': 'Patient reporting general health status per EORTC QLQ-C30', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.'}, {'measure': 'Patient reporting general health status per EORTC QLQ-CR29 in CRC patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.'}, {'measure': 'Patient reporting general health status per EORTC QLQ-BR23 in breast cancer patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': "The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems."}, {'measure': 'Patient reporting general health status per EORTC QLQ-LC13 in NSCLC patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain.\n\nThe scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much".'}, {'measure': 'Patient reporting general health status per EORTC QLQ-HN35 in HNSCC patients', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses.\n\nThe questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4.'}, {'measure': 'Patient reporting general health status per EQ-5D-5L', 'timeFrame': 'Approximately 90 days from last dose; up to 5 years', 'description': 'The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Variety of mixed advanced solid tumor types', 'First in Human (FIH)'], 'conditions': ['Advanced Solid Tumors']}, 'descriptionModule': {'briefSummary': 'This study is researching an investigational drug called REGN7075 by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable REGN7075 is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of REGN7075 to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective REGN7075 by itself, or in combination with cemiplimab (with or without chemotherapy), is at treating cancer patients.\n\nThe study is also looking at:\n\n* Side effects that may be experienced by people taking REGN7075 by itself and in combination with cemiplimab with or without chemotherapy\n* How REGN7075 works in the body by itself and in combination with cemiplimab with or without chemotherapy\n* How much REGN7075 is present in the blood when given by itself and in combination with cemiplimab with or without chemotherapy\n* To see if REGN7075 by itself and in combination with cemiplimab with or without chemotherapy works to treat cancer by controlling the proliferation of tumor cells to shrink the tumor'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Key Inclusion Criteria:\n\n1. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n2. Has histologically or cytologically confirmed cancer that meets criteria as defined in the protocol\n3. Expansion Cohorts only: Is anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) naïve, defined as never having previously been treated with a drug that targets the PD-1\n4. Has at least 1 lesion that meets study criteria as defined in the protocol\n5. Willing to provide tumor tissue from newly obtained biopsy (at a minimum core biopsy) from a tumor site that has not been previously irradiated\n6. Has adequate organ and bone marrow function as defined in the protocol\n7. In the judgement of the investigator, has a life expectancy of at least 3 months\n\nKey Exclusion Criteria:\n\n1. Is currently participating in another study of a therapeutic agent\n2. Has participated in any study of an investigational agent or an investigational device within 4 weeks of the first administration of study drug as defined in the protocol\n3. Has received treatment with an approved systemic therapy within 4 weeks of the first administration of study drug or has not yet recovered (ie, grade 1 or baseline) from any acute toxicities\n4. Has received recent anti-epidermal growth factor receptor (EGFR) antibody therapy as defined in the protocol\n5. Has received radiation therapy or major surgery within 14 days of the first administration of study drug or has not recovered (ie, grade 1 or baseline) from adverse events\n6. Has received any previous systemic, non-immunomodulatory biologic therapy within 4 weeks of first administration of study drug.\n7. Has had prior anti-cancer immunotherapy within 5 half-lives prior to study drug as defined in the protocol\n8. Has second malignancy that is progressing or requires active treatment as defined in the protocol\n9. Has any condition requiring ongoing/continuous corticosteroid therapy (\\>10 mg prednisone/day or anti-inflammatory equivalent) within 1-2 weeks prior to the first dose of study drug as defined in the protocol\n10. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease or any other condition that required treatment with systemic immunosuppressive treatments as defined in the protocol\n11. Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression\n12. Has encephalitis, meningitis, organic brain disease (eg, Parkinson's disease) or uncontrolled seizures within 1 year prior to the first dose of study drug\n13. Has any ongoing inflammatory skin disease as defined in the protocol\n\nNOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply"}, 'identificationModule': {'nctId': 'NCT04626635', 'acronym': 'COMBINE-EGFR-1', 'briefTitle': 'A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers', 'organization': {'class': 'INDUSTRY', 'fullName': 'Regeneron Pharmaceuticals'}, 'officialTitle': 'A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors', 'orgStudyIdInfo': {'id': 'R7075-ONC-2009'}, 'secondaryIdInfos': [{'id': '2022-501234-37-00', 'type': 'OTHER', 'domain': 'EU CTR-CTIS'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Dose Escalation', 'description': 'Variety of mixed advanced solid tumor types', 'interventionNames': ['Drug: REGN7075', 'Drug: Cemiplimab']}, {'type': 'EXPERIMENTAL', 'label': 'Dose Expansion A', 'description': 'Triple Negative Breast Cancer (TNBC)', 'interventionNames': ['Drug: REGN7075', 'Drug: Cemiplimab']}, {'type': 'EXPERIMENTAL', 'label': 'Dose Expansion B', 'description': 'Cutaneous Squamous Cell Carcinoma (CSCC)', 'interventionNames': ['Drug: REGN7075', 'Drug: Cemiplimab']}, {'type': 'EXPERIMENTAL', 'label': 'Dose Expansion C', 'description': 'Non-Small Cell Lung Cancer (NSCLC)', 'interventionNames': ['Drug: REGN7075', 'Drug: Cemiplimab', 'Drug: Platinum-based doublet chemotherapy']}, {'type': 'EXPERIMENTAL', 'label': 'Dose Expansion D', 'description': 'Head and Neck Squamous Cell Carcinoma (HNSCC)', 'interventionNames': ['Drug: REGN7075', 'Drug: Cemiplimab']}, {'type': 'EXPERIMENTAL', 'label': 'Dose Expansion E', 'description': 'Microsatellite Stable-Colorectal Cancer (MSS-CRC), with Active Liver Metastases and/or Active Peritoneal Metastases', 'interventionNames': ['Drug: REGN7075', 'Drug: Cemiplimab']}, {'type': 'EXPERIMENTAL', 'label': 'Dose Expansion F', 'description': 'MSS-CRC with Isolated Lung/Lymph Node Metastases (no active liver and no active peritoneal metastases)', 'interventionNames': ['Drug: REGN7075', 'Drug: Cemiplimab']}, {'type': 'EXPERIMENTAL', 'label': 'Dose Expansion G', 'description': 'Epidermal Growth Factor Receptor (EGFR) -mutant NSCLC Post Third Generation tyrosine kinase inhibitor (TKI)', 'interventionNames': ['Drug: REGN7075', 'Drug: Cemiplimab', 'Drug: Platinum-based doublet chemotherapy']}, {'type': 'EXPERIMENTAL', 'label': 'Dose Expansion H', 'description': 'EGFR-mutant NSCLC Post Third Generation TKI and Post Platinum-Doublet Chemotherapy', 'interventionNames': ['Drug: REGN7075', 'Drug: Cemiplimab']}, {'type': 'EXPERIMENTAL', 'label': 'Dose Expansion I', 'description': 'Third-line (3L) MSS-CRC with Active Liver Metastases', 'interventionNames': ['Drug: REGN7075', 'Drug: Cemiplimab', 'Drug: Bevacizumab', 'Drug: Trifluridine-tipiracil']}, {'type': 'EXPERIMENTAL', 'label': 'Dose Expansion J', 'description': '3L MSS-CRC without Active Liver Metastases', 'interventionNames': ['Drug: REGN7075', 'Drug: Cemiplimab', 'Drug: Bevacizumab', 'Drug: Trifluridine-tipiracil']}], 'interventions': [{'name': 'REGN7075', 'type': 'DRUG', 'description': 'Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)', 'armGroupLabels': ['Dose Escalation', 'Dose Expansion A', 'Dose Expansion B', 'Dose Expansion C', 'Dose Expansion D', 'Dose Expansion E', 'Dose Expansion F', 'Dose Expansion G', 'Dose Expansion H', 'Dose Expansion I', 'Dose Expansion J']}, {'name': 'Cemiplimab', 'type': 'DRUG', 'otherNames': ['REGN2810', 'Libtayo'], 'description': 'Administered concomitantly Q3W by IV infusion or SC injection', 'armGroupLabels': ['Dose Escalation', 'Dose Expansion A', 'Dose Expansion B', 'Dose Expansion C', 'Dose Expansion D', 'Dose Expansion E', 'Dose Expansion F', 'Dose Expansion G', 'Dose Expansion H', 'Dose Expansion I', 'Dose Expansion J']}, {'name': 'Platinum-based doublet chemotherapy', 'type': 'DRUG', 'description': 'Administered IV Q3W', 'armGroupLabels': ['Dose Expansion C', 'Dose Expansion G']}, {'name': 'Bevacizumab', 'type': 'DRUG', 'description': 'Administered per protocol', 'armGroupLabels': ['Dose Expansion I', 'Dose Expansion J']}, {'name': 'Trifluridine-tipiracil', 'type': 'DRUG', 'description': 'Administered per protocol', 'armGroupLabels': ['Dose Expansion I', 'Dose Expansion J']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90067', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Valkyrie Clinical Trials', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '90095', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of California Los Angeles (UCLA) Medical Center', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '94118', 'city': 'San Francisco', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'The Regents of the University of California, San Francisco', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Colorado Hospital - Anschutz Cancer Pavilion - Lung Cancer Clinic', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '32608', 'city': 'Gainesville', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Florida Health', 'geoPoint': {'lat': 29.65163, 'lon': -82.32483}}, {'zip': '33612', 'city': 'Tampa', 'state': 'Florida', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Moffitt Cancer Center', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '60612', 'city': 'Chicago', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Illinois Cancer Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Iowa Hospitals and Clinics', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '02215', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'Dana Farber Cancer Institute Brookline Avenue', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '49546', 'city': 'Grand Rapids', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'START Midwest - Cancer & Hematology Centers of Western Michigan, PC', 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'zip': '08901', 'city': 'New Brunswick', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Rutgers Cancer Institute of New Jersey', 'geoPoint': {'lat': 40.48622, 'lon': -74.45182}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Memorial Sloan Kettering Cancer Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '45219', 'city': 'Cincinnati', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Cincinnati Medical Center', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '43212', 'city': 'Columbus', 'state': 'Ohio', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'The Stefanie Spielman Comprehensive Breast Center', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '19111', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Fox Chase Cancer Center', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '37203', 'city': 'Nashville', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Sarah Cannon Research Institute - 25th Ave', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'MD Anderson Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'South Texas Oncology And Hematology', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '98109', 'city': 'Seattle', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Washington/Fred Hutchinson Cancer Center', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '53226', 'city': 'Milwaukee', 'state': 'Wisconsin', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Medical College of Wisconsin', 'geoPoint': {'lat': 43.0389, 'lon': -87.90647}}, {'zip': '69008', 'city': 'Lyon', 'state': 'Auvergne-Rhone', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Centre Leon Berard (CLB) - Centre de Recherche en Cancerologie Lyon-Est (CRCL)', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '63011', 'city': 'Clermont-Ferrand', 'state': 'Auvergne-Rhône', 'status': 'WITHDRAWN', 'country': 'France', 'facility': 'Centre Jean Perrin', 'geoPoint': {'lat': 45.77969, 'lon': 3.08682}}, {'zip': '69310', 'city': 'Pierre-Bénite', 'state': 'Auvergne-Rhône', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Hopital Lyon Sud', 'geoPoint': {'lat': 45.70359, 'lon': 4.82424}}, {'zip': '21034', 'city': 'Dijon', 'state': 'Bourgogne-Franche-Comté', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Centre Georges Francois Leclerc', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'zip': '31059', 'city': 'Toulouse', 'state': 'Haute-Garonne', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Institut Claudius Regaud, IUCT-Oncopole', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '33076', 'city': 'Bordeaux', 'state': 'Nouvelle-Aquitaine', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Institut Bergonie', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'zip': '86021', 'city': 'Poitiers', 'state': 'Nouvelle-Aquitaine', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire (CHU) de Poitiers', 'geoPoint': {'lat': 46.58261, 'lon': 0.34348}}, {'zip': '44093', 'city': 'Nantes', 'state': 'Pays de la Loire Region', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Nantes University Hospital', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '06189', 'city': 'Nice', 'state': 'Provence Alpes Cote dAzur', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Centre Antoine Lacassagne', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'zip': '75014', 'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Hospital Paris Saint-Joseph', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '94240', 'city': 'Saint-Mandé', 'state': 'Île-de-France Region', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Begin Army Instruction Hospital', 'geoPoint': {'lat': 48.83864, 'lon': 2.41579}}, {'zip': '94800', 'city': 'Villejuif', 'state': 'Île-de-France Region', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Gustave Roussy', 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}, {'zip': '5265601', 'city': 'Ramat Gan', 'state': 'Central District', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Sheba Medical Center'}, {'zip': '84101', 'city': 'Beersheba', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Soroka University Medical Center', 'geoPoint': {'lat': 31.25181, 'lon': 34.7913}}, {'zip': '3109601', 'city': 'Haifa', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Rambam Health Care Campus', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '9103102', 'city': 'Jerusalem', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Shaare Zedek Medical Center', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '91220', 'city': 'Jerusalem', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Hadassah Medical Center', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '64239', 'city': 'Tel Aviv', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Tel Aviv Sourasky Medical Center', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'zip': '1066 CX', 'city': 'Amsterdam', 'status': 'RECRUITING', 'country': 'Netherlands', 'facility': 'Netherlands Cancer Institute', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'zip': '3015 GD', 'city': 'Rotterdam', 'status': 'RECRUITING', 'country': 'Netherlands', 'facility': 'Erasmus MC', 'geoPoint': {'lat': 51.9225, 'lon': 4.47917}}, {'zip': '60-693', 'city': 'Poznan', 'state': 'Wielkopolska', 'status': 'RECRUITING', 'country': 'Poland', 'facility': 'Medpolonia Sp. z o.o.', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '70-784', 'city': 'Szczecin', 'state': 'Zach', 'status': 'RECRUITING', 'country': 'Poland', 'facility': 'Dom Lekarski SA', 'geoPoint': {'lat': 53.42894, 'lon': 14.55302}}, {'zip': '08195', 'city': 'Sant Cugat del Vallès', 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital General de Catalunya', 'geoPoint': {'lat': 41.47063, 'lon': 2.08611}}, {'zip': '28223', 'city': 'Pozuelo de Alarcón', 'state': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital Universitario Quiron Salud Madrid', 'geoPoint': {'lat': 40.43293, 'lon': -3.81338}}, {'zip': '08035', 'city': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'facility': "Hospital Universitari Vall d'Hebron", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28002', 'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Genesis Care Hospital San Francisco de Asis', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28040', 'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital Clinico San Carlos', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28040', 'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital Universitario Fundacion Jimenez Diaz', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28041', 'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital 12 de Octubre', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28040', 'city': 'Valencia', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital Clinico Universitario - University of Valencia', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': '01120', 'city': 'Yüreğir', 'state': 'Adana', 'status': 'RECRUITING', 'country': 'Turkey (Türkiye)', 'facility': 'Baskent Universitesi', 'geoPoint': {'lat': 36.97439, 'lon': 35.35916}}, {'zip': '06200', 'city': 'Ankara', 'status': 'RECRUITING', 'country': 'Turkey (Türkiye)', 'facility': 'Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'zip': '34450', 'city': 'Istanbul', 'status': 'WITHDRAWN', 'country': 'Turkey (Türkiye)', 'facility': 'Istanbul University Cerrahpasa at Cerrahpasa Medical Faculty', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '81450', 'city': 'Istanbul', 'status': 'RECRUITING', 'country': 'Turkey (Türkiye)', 'facility': 'Istanbul Medeniyet University - Prof Dr Suleyman Yalcin Sehir Hospital', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '33343', 'city': 'Mersin', 'status': 'RECRUITING', 'country': 'Turkey (Türkiye)', 'facility': 'Ciftlikkoy Campus Yenisehir Mersin', 'geoPoint': {'lat': 36.81196, 'lon': 34.63886}}], 'centralContacts': [{'name': 'Clinical Trials Administrator', 'role': 'CONTACT', 'email': 'clinicaltrials@regeneron.com', 'phone': '844-734-6643'}], 'overallOfficials': [{'name': 'Clinical Trial Management', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Regeneron Pharmaceuticals'}]}, 'ipdSharingStatementModule': {'url': 'https://vivli.org/', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR', 'ANALYTIC_CODE'], 'timeFrame': 'When Regeneron has:\n\n* received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development\n* made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry),\n* the legal authority to share the data,\n* ensured the ability to protect participant privacy.', 'ipdSharing': 'YES', 'description': 'All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing', 'accessCriteria': "Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf"}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Regeneron Pharmaceuticals', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}